Egesa W.I. .2022 .Sickle Cell Disease in Children and Adolescents: A Review of the Historical, Clinical, and Public Health Perspective of Sub-Saharan Africa and Beyond. International Journal of Pediatrics, : .
Almanasif M.A.,Newborn M.A. .2024 .Screening of Hemoglobinopathies Using Mass Spectrometry in Saudi Arabia. , : .
Alharbi R.A. . .The Prevalence of Neonatal Anemia in Al Baha, Saudi Arabia: A Retrospective Observational Study. The Egyptian Journal of Haematology, 48(2023) : 253-259.
Makkawi M. .2021 .. Hemoglobinopathies: An Update on the Prevalence Trends in Southern Saudi Arabia.” Saudi Medical Journal, 42(2021) : 784-789.
Alghamdi F.A. . .Risk Factors for Acute Chest Syndrome among Children with Sickle Cell Anemia Hospitalized for Vaso-Occlusive Crises. Scientific Reports, 14(2024) : 5978.
Sabina M. .2024 .Vaso-Occlusive Crises in Sickle Cell Trait Patients with Blood Loss Anemia: A Report of Two Cases. , 16(3) : .
van Tuijn ,C.F.J. .2017 .Prospective Evaluation of Chronic Organ Damage in Adult Sickle Cell Patients: A Seven-Year Follow-Up Study. American Journal of Hematology, 92(10) : E584-E590.
Barton F. .2003 .Effect of Hydroxyurea on Mortality and Morbidity in Adult Sickle Cell Anemia. ” JAMA, 289(13) : 1645-1651.
Gohal G.A. .2022 .Utilization of Hydroxyurea among Patients Diagnosed with Sickle Cell Disease in Jazan, Saudi Arabia. Patient Preference and Adherence, : 3059-3067.
Pizzo A. . .Provider Prescription of Hydroxyurea in Youth and Adults with Sickle Cell Disease: A Review of Prescription Barriers and Facilitators. British Journal of Haematology, 203(2023) : 712-721.
Alherz I.H. .2024 .Utilization and Perceptions of Hydroxyurea Therapy among Adult Patients with Sickle Cell Disease in Al Ahsa, Saudi Arabia: A Cross-Sectional Study. ” Cureus, 16(7) : .
Kroner B.L. . .Pregnancy Outcomes with Hydroxyurea Use in Women with Sickle Cell Disease. American Journal of Hematology, 97(2022) : 603-612.
Rubio Lopez,M. Lopez,Marina and M. Arguello .2024 .The Current Role of Hydroxyurea in the Treatment of Sickle Cell Anemia. ” Journal of Clinical Medicine, 13(21) : 6404.
Yawn B.P. .2014 .. Management of Sickle Cell Disease: Summary of the 2014 Evidence-Based Report by Expert Panel Members.” JAMA, 10517(10) : 1033-1048.
Borhade M.B.,Patel P.,Kondamudi N.P. .2024 .. StatPearls Publishing, : .
Weaver S.B. . .Contemporary Management and Prevention of Vaso-Occlusive Crises (VOCs) in Adults with Sickle Cell Disease. ” Journal of Pharmacy Practice, 36(2023) : 139-148.
Sahu A. .2022 .Defining Vitamin D Deficiency in Patients with Sickle Cell Disease: A Meta-Analysis. ” Journal of Parathyroid Disease, 11154(2022) : e11154.
Piel F.B. . .Defining Global Strategies to Improve Outcomes in Sickle Cell Disease: A Lancet Haematology Commission.” The Lancet Haematology. , 3026(23) : 00171-1.
Ware R.E. .2017 .. Sickle Cell Disease.” The Lancet, 6736(17) : 30193-9.
Pule G.D. .2015 .A Systematic Review of Known Mechanisms of Hydroxyurea-Induced Fetal Hemoglobin for Treatment of Sickle Cell Disease. ” Expert Review of Hematology, 1063428(2015) : 669-679.
Plett R. . .Empowering Patients with Sickle Cell Anemia and Their Families through Innovative Educational Methods. EJHaem, 4(2023) : 678-955.
Geway G.,Ferdjallah A.,Supplement 1 .2024 .Sickle Cell Patient Education Materials. ” Journal of Sickle Cell Disease, 1 : .
King K. .2023 .Barriers to Medication Adherence in Sickle Cell Disease: A Comprehensive Theory-Based Evaluation Using the COM-B Model. Pediatric Blood & Cancer, : .
Alkanhal H. .2014 .Adherence to Hydroxyurea Therapy in Patients with Sickle Cell Disease. ” Journal of Blood Disorders and Transfusion, 5(2) : 1000202-9864.